STOCKRETAIL-DRUG STORES AND PROPRIETARY STORESUpdated 2026-08-23
Here’s whether CVS HEALTH CORPORATION (CVS) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+0.14% over 10 days); strong 1-year return of +30.2%. Concerns: below the 50-day MA (medium-term momentum negative); RSI 21 — oversold. Currently 16.0% off its 52-week high. Score: +2/7.
CVS is holding above its long-term 200-day MA ($85.74) but has slipped below the 50-day MA ($102.01), pointing to short-term weakness in an otherwise intact trend. An RSI of 21.2 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +30.2% compares to +20.5% for SPY (beat the market by 9.8%).
$10,000 invested 1 year ago→ $13,023 today
vs. S&P 500 (SPY) — same period beat market by 9.8%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($85.74)
✗Above 50-day MA ($102.01)
!RSI(14) neutral zone (30–70) — currently 21.2
✓Positive return (+30.2%)
!Within 10% of period high (−16.0%)
Period Range $93.02
$69.51$110.68
RSI (14) 21.2
0 · OversoldOverbought · 100
Key Metrics
Price$93.02
Period Return+30.2%
Period High$110.68
Period Low$69.51
Drawdown−16.0%
MA-50$102.01
MA-200$85.74
RSI (14)21.2
Avg Volume (30d)8.2M
vs. SPYbeat by 9.8%
Return Rank#341 of 999
Trend Signals
Price is above the 200-day moving average ($85.74)
Price is below the 50-day moving average ($102.01)